News

Dosing Begins in Phase 1 Trial of CERC-007

Cerecor has dosed the first patient in a Phase 1b clinical trial evaluating  CERC-007 as a potential treatment for relapsed or refractory multiple myeloma. The trial (NCT04671251) intends to enroll up to 30 adult patients who received prior treatment with a proteasome inhibitor, an immunomodulatory agent, and…

Jakafi Plus Steroid Continuing to Treat Multiple Myeloma in Phase 1 Trial

Combining the corticosteroid methylprednisolone and Jakafi (ruxolitinib), an approved oral therapy for bone marrow disorders, is showing promising effectiveness in heavily pre-treated multiple myeloma patients in an ongoing Phase 1 trial. Findings to date from this open-label study (NCT03110822), which is being sponsored by Onco Therapeutics, showed…

$10M Gift to Open Myeloma Research Center at Ohio State

A new research center at Ohio State University (OSU) aims to speed work into the discovery and development of more effective treatments for those with multiple myeloma. The Riney Family Foundation Myeloma Center for Advanced Research Excellence (Myeloma CARE) is being established through a $10 million gift from the…

First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy

The first patient has been dosed in Celyad Oncology’s Phase 1 clinical trial evaluating CYAD-211, an investigational donor-derived CAR T-cell therapy for treating relapsed or refractory multiple myeloma. The IMMUNICY-1 trial (NCT04613557) intends to recruit 12 patients who received two or more prior lines of treatment, including…

FDA Gives Orphan Drug Status to Potential Multiple Myeloma Immunotherapy

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harpoon Therapeutics‘ investigational immunotherapy HPN217 as a possible treatment of multiple myeloma. The designation encourages the development of potential therapies for rare and serious diseases by granting them various financial and regulatory benefits. These include exemptions from…

First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo

The first participant has been dosed in a Phase 3 trial investigating a triple combination of melflufen (melphalan flufenamide) plus dexamethasone and under-the-skin Darzalex (daratumumab) in people with heavily treated multiple myeloma. The trial, dubbed LIGHTHOUSE (NCT04649060), had been delayed by the COVID-19 pandemic but is now…

PT-112 Shows Promise for Heavily Treated Myeloma Patients

Phosplatin Therapeutics‘ investigational medication PT-112 showed promising efficacy and safety data in an early clinical trial of heavily-pretreated people with relapsed or refractory multiple myeloma. The findings were shared in a presentation, “A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or…

FDA Approval Sought for Cilta-cel CAR T-cell Therapy

Janssen and Legend Biotech are seeking U.S. approval for their investigational CAR T-cell therapy ciltacabtagene autoleucel  — known as cilta-cel — to treat adults with relapsed or refractory (hard-to-treat) multiple myeloma. A rolling submission of the biologics license application (BLA) for cilta-cel has been started by Janssen…